Neurocrine Biosciences Company Profile (NASDAQ:NBIX)

About Neurocrine Biosciences (NASDAQ:NBIX)

Neurocrine Biosciences logoNeurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson's disease. Its product pipeline also includes NBI-640756, which targets tremor and NBI-74788, which targets classic congenital adrenal hyperplasia. Its R&D focus is on addressing diseases and disorders of the central nervous and endocrine systems.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:NBIX
  • CUSIP: 64125C10
  • Web:
  • Market Cap: $4.32 billion
  • Outstanding Shares: 88,075,000
Average Prices:
  • 50 Day Moving Avg: $46.06
  • 200 Day Moving Avg: $45.96
  • 52 Week Range: $37.35 - $55.38
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -34.03
  • P/E Growth: -0.40
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $2.82 per share
  • Price / Book: 17.38
  • EBIDTA: ($204,780,000.00)
  • Return on Equity: -61.84%
  • Return on Assets: -53.97%
  • Current Ratio: 10.16%
  • Quick Ratio: 10.16%
  • Average Volume: 1.15 million shs.
  • Beta: 0.42
  • Short Ratio: 7.44
Frequently Asked Questions for Neurocrine Biosciences (NASDAQ:NBIX)

What is Neurocrine Biosciences' stock symbol?

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) released its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.67) by $0.23. During the same period last year, the business posted ($0.22) EPS. View Neurocrine Biosciences' Earnings History.

Where is Neurocrine Biosciences' stock going? Where will Neurocrine Biosciences' stock price be in 2017?

17 equities research analysts have issued twelve-month target prices for Neurocrine Biosciences' shares. Their predictions range from $55.00 to $100.00. On average, they anticipate Neurocrine Biosciences' share price to reach $67.69 in the next twelve months. View Analyst Ratings for Neurocrine Biosciences.

What are analysts saying about Neurocrine Biosciences stock?

Here are some recent quotes from research analysts about Neurocrine Biosciences stock:

  • 1. Cowen and Company analysts commented, "NBIX remains well funded, ending Q4 with $352MM in cash." (2/15/2017)
  • 2. Robert W. Baird analysts commented, "No change to outlook heading into Ingrezza approval. Neurocrine reported a solid end to the year, modestly beating estimates on lower-than-expected opex. Though we are only a few weeks into 2017, it has already been a busy year for NBIX. Expect the year to continue to bring multiple updates, from potential approval of Ingrezza in TD and Tourette data in May to Phase 3 UF data for elagolix near year-end, an elagolix NDA submission, advances in CAH and essential tremor, and FDA discussions on newly licensed opicapone' Earnings and spend in-line, expect accelerations into launch. 4Q16 EPS of ($0.51) modestly beat our/consensus estimates of ($0.54)/($0.57), respectively, due to lower than projected operating expenses. Looking ahead to 2017, management expects opex to increase to about $230M-$240M due activities surrounding the launch of Ingrezza." (2/15/2017)
  • 3. Needham & Company LLC analysts commented, "Company continues to prepare for Ingrezza launch ahead of 4/11/17 PDUFA date. We expect approval based on strength of Phase 3 data, followed by launch ~6wks later. We believe Boxed Warning/ REMS are possible. Phase 2 pediatric Tourette Syndrome (TS) data are expected May 2017 (was Apr). Given efficacy trend observed in adult Phase 2 TS, we believe Ingrezza will likely be active in pediatric TS as well. Elagolix NDA submission for Endometriosis by Abbvie is expected 3Q17 (was 2H17), triggering a $30M payment to Neurocrine. Phase 3 results in Uterine Fibroids are expected by YE17. We believe stock is attractive ahead of near term events. BUY." (2/10/2017)
  • 4. HC Wainwright analysts commented, "We expect FDA to agree in early 2017 that Atara has demonstrated comparability between clinical batches of ATA-129, or EBV-CTL, and the prior material produced at MSKCC, paving the way for Phase 3 start. We believe comparability data will include the number of cells to administer, cytoreactivity, cell storage time, restriction studies (HLA types), variability based on release criteria, and the methods by which data are collected. CMC amendment standard for new clinical material Importantly, a CMC amendment is standard practice for an IND when new clinical material is introduced; therefore, we view Atara’s process as normal." (1/18/2017)
  • 5. Jefferies Group LLC analysts commented, "While the study showed a stat sig improvement on the Clinical Global Impression of Change scale (CGI; p=0.015), the study did not reach stat sig on the 1EP of Yale Global Tic Severity Scale (YGTSS; p=0.18). No further trial details were released. Although a setback, we note that this does not directly read through to the pediatric study readout expected in April." (1/18/2017)

Who are some of Neurocrine Biosciences' key competitors?

Who are Neurocrine Biosciences' key executives?

Neurocrine Biosciences' management team includes the folowing people:

  • William H. Rastetter Ph.D., Independent Chairman of the Board
  • David-Alexandre C. Gros M.D., President, Interim Chief Financial Officer, Chief Operating Officer
  • Kevin C. Gorman Ph.D., Chief Executive Officer, Director
  • Eric S. Benevich, Chief Commercial Officer
  • Haig P. Bozigian Ph.D., Chief Development Officer
  • Kyle Gano Ph.D., Chief Business Development Officer
  • Dimitri E. Grigoriadis Ph.D., Chief Research Officer
  • Malcolm Lloyd-Smith, Chief Regulatory Officer
  • Christopher F. O'Brien M.D., Chief Medical Officer
  • Darin M. Lippoldt, Corporate Secretary

Who owns Neurocrine Biosciences stock?

Neurocrine Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Public Employees Retirement Association of Colorado (0.32%), NN Investment Partners Holdings N.V. (0.24%), Handelsbanken Fonder AB (0.17%), GW&K Investment Management LLC (0.09%), Handelsinvest Investeringsforvaltning (0.05%) and Aperio Group LLC (0.03%). Company insiders that own Neurocrine Biosciences stock include Christopher Flint Obrien, Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Gary A Lyons, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Richard F Pops, Timothy P Coughlin and William H Rastetter. View Institutional Ownership Trends for Neurocrine Biosciences.

Who sold Neurocrine Biosciences stock? Who is selling Neurocrine Biosciences stock?

Neurocrine Biosciences' stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., GW&K Investment Management LLC, Capstone Asset Management Co., Independent Portfolio Consultants Inc. and Creative Planning. Company insiders that have sold Neurocrine Biosciences stock in the last year include Christopher Flint Obrien, Corinne H Nevinny, Dimitri E Grigoriadis, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Timothy P Coughlin and William H Rastetter. View Insider Buying and Selling for Neurocrine Biosciences.

Who bought Neurocrine Biosciences stock? Who is buying Neurocrine Biosciences stock?

Neurocrine Biosciences' stock was purchased by a variety of institutional investors in the last quarter, including NN Investment Partners Holdings N.V., Public Employees Retirement Association of Colorado, Handelsbanken Fonder AB, Handelsinvest Investeringsforvaltning and Aperio Group LLC. View Insider Buying and Selling for Neurocrine Biosciences.

How do I buy Neurocrine Biosciences stock?

Shares of Neurocrine Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Neurocrine Biosciences' stock price today?

One share of Neurocrine Biosciences stock can currently be purchased for approximately $49.00.

MarketBeat Community Rating for Neurocrine Biosciences (NASDAQ NBIX)
Community Ranking:  4.4 out of 5 (   )
Outperform Votes:  508 (Vote Outperform)
Underperform Votes:  66 (Vote Underperform)
Total Votes:  574
MarketBeat's community ratings are surveys of what our community members think about Neurocrine Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Neurocrine Biosciences (NASDAQ:NBIX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 16 Buy Ratings
Consensus Rating:Buy (Score: 2.94)
Consensus Price Target: $67.69 (38.14% upside)

Analysts' Ratings History for Neurocrine Biosciences (NASDAQ:NBIX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/5/2017Oppenheimer Holdings, Inc.Reiterated RatingOutperform$70.00LowView Rating Details
5/30/2017Jefferies Group LLCReiterated RatingBuy$66.00LowView Rating Details
5/24/2017Piper Jaffray CompaniesSet Price TargetBuy$68.00MediumView Rating Details
5/24/2017J P Morgan Chase & CoSet Price TargetBuy$57.00MediumView Rating Details
5/25/2017BMO Capital MarketsReiterated RatingOutperform$75.00LowView Rating Details
5/25/2017Leerink SwannLower Price TargetOutperform$68.00 -> $66.00LowView Rating Details
5/24/2017Needham & Company LLCReiterated RatingBuy$62.00 -> $58.00LowView Rating Details
5/15/2017Bank of America CorporationReiterated RatingBuy$70.00MediumView Rating Details
5/2/2017Barclays PLCBoost Price TargetOverweight$60.00 -> $70.00LowView Rating Details
4/14/2017Robert W. BairdReiterated RatingOutperform$66.00N/AView Rating Details
3/7/2017Cantor FitzgeraldReiterated RatingOverweight$80.00N/AView Rating Details
2/16/2017HC WainwrightBoost Price TargetPositive$80.00 -> $100.00N/AView Rating Details
2/15/2017Cowen and CompanyReiterated RatingBuyN/AView Rating Details
2/10/2017ICAPReiterated RatingOutperform$55.00N/AView Rating Details
1/27/2017CIBCUpgradeMarket Perform -> OutperformN/AView Rating Details
1/19/2017Deutsche Bank AGReiterated RatingBuy$65.00 -> $62.00N/AView Rating Details
11/22/2016Citigroup Inc.Initiated CoverageMarket Perform$55.00N/AView Rating Details
11/2/2015NomuraBoost Price TargetBuy$34.00 -> $43.00N/AView Rating Details
(Data available from 7/26/2015 forward)


Earnings History for Neurocrine Biosciences (NASDAQ:NBIX)
Earnings by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)
Earnings History by Quarter for Neurocrine Biosciences (NASDAQ NBIX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 17($0.67)($0.90)$3.00 millionViewListenView Earnings Details
2/14/2017Q416($0.55)($0.51)$4.55 millionViewListenView Earnings Details
11/2/2016Q316($0.57)($0.43)ViewN/AView Earnings Details
5/5/2016Q1($0.29)($0.22)$15.43 million$15.00 millionViewN/AView Earnings Details
2/11/2016Q415($0.32)($0.34)$3.33 millionViewListenView Earnings Details
10/29/2015Q315($0.25)($0.40)$6.66 millionViewListenView Earnings Details
7/29/2015Q2($0.29)($0.28)$0.41 millionViewListenView Earnings Details
4/30/2015Q115($0.30)($0.01)$19.76 millionViewN/AView Earnings Details
2/9/2015Q414($0.24)($0.26)ViewN/AView Earnings Details
11/3/2014Q314($0.21)($0.21)ViewN/AView Earnings Details
8/6/2014Q214($0.18)($0.18)$0.12 millionViewN/AView Earnings Details
4/30/2014Q114($0.19)($0.17)$0.78 millionViewN/AView Earnings Details
2/6/2014Q413($0.17)($0.16)$0.79 million$0.73 millionViewN/AView Earnings Details
10/29/2013Q313($0.20)($0.17)$0.79 million$0.73 millionViewN/AView Earnings Details
7/25/2013Q2 2013($0.20)($0.18)$0.77 million$0.73 millionViewListenView Earnings Details
5/2/2013Q1 2013($0.18)($0.18)$1.07 million$0.70 millionViewListenView Earnings Details
2/8/2013Q4 2012($0.08)$0.14$9.43 million$21.90 millionViewListenView Earnings Details
10/31/2012Q312($0.05)($0.05)$10.28 million$9.40 millionViewN/AView Earnings Details
7/31/2012($0.03)($0.01)ViewN/AView Earnings Details
5/2/2012($0.01)ViewN/AView Earnings Details
10/31/2011$0.19$0.56ViewN/AView Earnings Details
7/28/2011$0.04$0.04ViewN/AView Earnings Details
5/3/2011$0.05$0.05ViewN/AView Earnings Details
2/10/2011$0.04$0.05ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Neurocrine Biosciences (NASDAQ:NBIX)
2017 EPS Consensus Estimate: ($2.31)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($0.89)($0.54)($0.65)
Q2 20174($0.68)($0.61)($0.65)
Q3 20174($0.72)($0.28)($0.50)
Q4 20174($0.76)($0.28)($0.52)
(Data provided by Zacks Investment Research)


Dividend History for Neurocrine Biosciences (NASDAQ:NBIX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Neurocrine Biosciences (NASDAQ:NBIX)
Insider Ownership Percentage: 4.80%
Institutional Ownership Percentage: 96.24%
Insider Trades by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)
Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)
Insider Trades by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/23/2017Dimitri E GrigoriadisInsiderSell10,000$53.39$533,900.00View SEC Filing  
5/19/2017Malcolm Lloyd-SmithInsiderSell9,960$53.63$534,154.80View SEC Filing  
5/5/2017Corinne H NevinnyDirectorSell5,000$53.98$269,900.00View SEC Filing  
5/2/2017Dimitri E GrigoriadisInsiderSell10,000$55.00$550,000.00View SEC Filing  
5/2/2017Kevin Charles GormanCEOSell21,739$53.23$1,157,166.97View SEC Filing  
5/1/2017Kyle GanoInsiderSell15,000$54.00$810,000.00View SEC Filing  
4/12/2017Haig P BozigianInsiderSell13,065$50.42$658,737.30View SEC Filing  
4/12/2017Kevin Charles GormanCEOSell19,596$50.42$988,030.32View SEC Filing  
2/7/2017Malcolm Lloyd-SmithInsiderSell116$44.61$5,174.76View SEC Filing  
2/6/2017Dimitri E GrigoriadisInsiderSell727$43.13$31,355.51View SEC Filing  
2/6/2017Kevin Charles GormanCEOSell3,010$43.18$129,971.80View SEC Filing  
2/6/2017Timothy P CoughlinCFOSell963$43.14$41,543.82View SEC Filing  
2/3/2017Christopher Flint ObrienInsiderSell1,500$42.50$63,750.00View SEC Filing  
2/3/2017Kevin Charles GormanCEOSell3,125$42.55$132,968.75View SEC Filing  
2/1/2017William H RastetterDirectorSell10,750$42.28$454,510.00View SEC Filing  
1/17/2017Haig P BozigianInsiderSell1,625$40.63$66,023.75View SEC Filing  
1/17/2017Kevin Charles GormanCEOSell3,750$40.65$152,437.50View SEC Filing  
1/17/2017Timothy P CoughlinCFOSell1,750$40.65$71,137.50View SEC Filing  
1/10/2017Christopher Flint ObrienInsiderSell1,750$43.35$75,862.50View SEC Filing  
1/10/2017Kevin Charles GormanCEOSell3,750$43.28$162,300.00View SEC Filing  
11/15/2016Christopher Flint ObrienInsiderSell25,000$52.84$1,321,000.00View SEC Filing  
9/1/2016Malcolm Lloyd-SmithInsiderSell9,000$50.00$450,000.00View SEC Filing  
8/15/2016Christopher Flint ObrienInsiderSell12,500$48.73$609,125.00View SEC Filing  
8/8/2016Corinne H NevinnyDirectorSell5,000$48.54$242,700.00View SEC Filing  
5/25/2016Richard F PopsDirectorSell15,000$46.72$700,800.00View SEC Filing  
5/16/2016Christopher Flint ObrienInsiderSell25,000$45.00$1,125,000.00View SEC Filing  
4/11/2016Kyle GanoInsiderSell41,770$44.02$1,838,715.40View SEC Filing  
4/6/2016Christopher Flint ObrienInsiderSell25,000$45.00$1,125,000.00View SEC Filing  
2/3/2016Haig P BozigianInsiderSell1,375$38.13$52,428.75View SEC Filing  
2/3/2016Kevin Charles GormanCEOSell3,125$38.04$118,875.00View SEC Filing  
2/3/2016Timothy P CoughlinCFOSell1,500$38.06$57,090.00View SEC Filing  
1/19/2016Haig P BozigianInsiderSell1,625$46.77$76,001.25View SEC Filing  
1/19/2016Kevin Charles GormanCEOSell3,750$46.70$175,125.00View SEC Filing  
1/19/2016Timothy P CoughlinCFOSell1,750$46.69$81,707.50View SEC Filing  
1/11/2016Haig P BozigianInsiderSell1,625$44.25$71,906.25View SEC Filing  
1/11/2016Kevin Charles GormanCEOSell3,750$44.17$165,637.50View SEC Filing  
1/11/2016Timothy P CoughlinCFOSell1,750$44.25$77,437.50View SEC Filing  
11/27/2015Dimitri E. GrigoriadisinsiderSell10,000$57.50$575,000.00View SEC Filing  
11/9/2015Darin LippoldtinsiderSell23,761$52.92$1,257,432.12View SEC Filing  
10/16/2015Haig P BozigianInsiderSell25,000$47.78$1,194,500.00View SEC Filing  
10/16/2015Kevin Charles GormanCEOSell33,500$47.77$1,600,295.00View SEC Filing  
9/18/2015Gary A. LyonsDirectorSell15,000$54.89$823,350.00View SEC Filing  
7/20/2015Dimitri E GrigoriadisInsiderSell19,646$55.00$1,080,530.00View SEC Filing  
7/20/2015Timothy P CoughlinCFOSell20,000$55.00$1,100,000.00View SEC Filing  
7/13/2015Dimitri E GrigoriadisInsiderSell10,000$50.00$500,000.00View SEC Filing  
7/13/2015Timothy P CoughlinCFOSell20,000$50.00$1,000,000.00View SEC Filing  
6/23/2015W Thomas MitchellDirectorSell15,000$49.35$740,250.00View SEC Filing  
6/8/2015Christopher Flint ObrienInsiderSell10,000$45.00$450,000.00View SEC Filing  
6/8/2015Timothy P CoughlinCFOSell60,000$45.08$2,704,800.00View SEC Filing  
3/24/2015Gary A LyonsDirectorSell30,000$41.53$1,245,900.00View SEC Filing  
3/24/2015Kevin Charles GormanCEOSell40,000$41.53$1,661,200.00View SEC Filing  
2/10/2015Dimitri E GrigoriadisInsiderSell20,000$35.00$700,000.00View SEC Filing  
1/16/2015Christopher Flint ObrienInsiderSell1,750$30.79$53,882.50View SEC Filing  
1/16/2015Kevin Charles GormanCEOSell3,750$30.79$115,462.50View SEC Filing  
1/12/2015Kevin Charles GormanCEOSell3,750$28.43$106,612.50View SEC Filing  
1/12/2015Kyle GanoInsiderSell1,250$28.41$35,512.50View SEC Filing  
1/12/2015Timothy P CoughlinCFOSell1,750$28.37$49,647.50View SEC Filing  
1/8/2015Dimitri E GrigoriadisInsiderSell30,000$27.35$820,500.00View SEC Filing  
1/8/2015Kevin Charles GormanCEOSell25,000$27.39$684,750.00View SEC Filing  
1/8/2015Timothy P CoughlinCFOSell10,000$27.25$272,500.00View SEC Filing  
1/5/2015Dimitri E GrigoriadisInsiderSell2,500$22.76$56,900.00View SEC Filing  
1/2/2015W Thomas MitchellDirectorSell8,000$22.79$182,320.00View SEC Filing  
12/19/2014Christopher Flint ObrienInsiderSell20,000$24.02$480,400.00View SEC Filing  
12/19/2014Kevin Charles GormanCEOSell70,000$23.41$1,638,700.00View SEC Filing  
12/19/2014Timothy P CoughlinCFOSell30,000$23.46$703,800.00View SEC Filing  
12/17/2014Kyle GanoInsiderSell4,957$22.50$111,532.50View SEC Filing  
12/15/2014Dimitri E GrigoriadisInsiderSell12,794$22.35$285,945.90View SEC Filing  
12/12/2014Kyle GanoInsiderSell4,043$22.50$90,967.50View SEC Filing  
12/11/2014Christopher Flint ObrienInsiderSell40,000$21.82$872,800.00View SEC Filing  
12/10/2014Timothy P CoughlinCFOSell20,000$21.48$429,600.00View SEC Filing  
12/10/2014W Thomas MitchellDirectorSell7,000$21.90$153,300.00View SEC Filing  
11/28/2014Timothy P CoughlinCFOSell10,000$20.14$201,400.00View SEC Filing  
11/24/2014Christopher Flint ObrienInsiderSell5,463$19.53$106,692.39View SEC Filing  
10/31/2014Timothy P CoughlinCFOSell10,000$19.00$190,000.00View SEC Filing  
10/30/2014Timothy P CoughlinCFOSell20,000$18.31$366,200.00View SEC Filing  
10/1/2014W Thomas MitchellDirectorSell1,275$15.50$19,762.50View SEC Filing  
9/15/2014Gary A LyonsDirectorSell20,000$15.66$313,200.00View SEC Filing  
1/17/2014Dimitri GrigoriadisInsiderSell25,000$20.00$500,000.00View SEC Filing  
1/10/2014Christopher Flint ObrienInsiderSell6,750$18.88$127,440.00View SEC Filing  
1/10/2014Kevin Charles GormanCEOSell3,750$18.57$69,637.50View SEC Filing  
1/10/2014Timothy CoughlinCFOSell1,750$18.56$32,480.00View SEC Filing  
1/7/2014Dimitri GrigoriadisInsiderSell25,000$17.50$437,500.00View SEC Filing  
1/7/2014Kevin Charles GormanCEOSell108,000$16.76$1,810,080.00View SEC Filing  
1/7/2014Timothy CoughlinCFOSell70,000$16.75$1,172,500.00View SEC Filing  
9/4/2013Kyle GanoInsiderSell2,400$15.61$37,464.00View SEC Filing  
9/3/2013Christopher Flint ObrienInsiderSell5,000$16.00$80,000.00View SEC Filing  
8/21/2013Haig BozigianInsiderSell13,999$15.04$210,544.96View SEC Filing  
8/21/2013Timothy CoughlinCFOSell19,035$15.05$286,476.75View SEC Filing  
8/6/2013W Thomas MitchellDirectorSell1,531$14.70$22,505.70View SEC Filing  
8/5/2013Haig BozigianInsiderSell11,001$15.00$165,015.00View SEC Filing  
8/5/2013Timothy CoughlinCFOSell10,965$14.99$164,365.35View SEC Filing  
7/12/2013Christopher Flint ObrienInsiderSell5,000$14.50$72,500.00View SEC Filing  
6/28/2013Christopher Flint ObrienInsiderSell11,357$13.33$151,388.81View SEC Filing  
6/27/2013Haig P BozigianInsiderSell8,000$13.00$104,000.00View SEC Filing  
6/21/2013Dimitri E GrigoriadisInsiderSell46,837$12.51$585,930.87View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Neurocrine Biosciences (NASDAQ:NBIX)
Latest Headlines for Neurocrine Biosciences (NASDAQ:NBIX)
DateHeadline logoToday's Research Reports on Stocks to Watch: Neurocrine Biosciences, Inc. and Ionis Pharmaceuticals - July 26 at 3:47 AM logoNeurocrine Biosciences, Inc. (NBIX) Given Consensus Recommendation of "Buy" by Brokerages - July 24 at 10:54 AM logo$1.56 Million in Sales Expected for Neurocrine Biosciences, Inc. (NBIX) This Quarter - July 22 at 10:57 AM logoNeurocrine Biosciences Announces the Appointment of Julie Cooke as Chief People Officer - PR Newswire (press release) - July 22 at 6:51 AM logoNeurocrine Biosciences Announces the Appointment of Julie Cooke as Chief People Officer - July 22 at 6:51 AM logoNeurocrine Biosciences Announces the Appointment of Julie Cooke as Chief People Officer - July 22 at 6:51 AM logoNeurocrine Poised To Corner Tardive Dyskinesia Market With Ingrezza - Seeking Alpha - July 11 at 3:05 AM logoNeurocrine Biosciences, Inc. (NBIX) Given "Outperform" Rating at Oppenheimer Holdings, Inc. - July 9 at 4:52 PM logoBayer Starts Phase III Study for Uterine Fibroids' Candidate - Nasdaq - Nasdaq - July 6 at 7:17 AM logoNeurocrine Biosciences: Ingrezza, Collaborations, Ratings - July 3 at 11:45 PM logoEdge Therapeutics (EDGE) versus Neurocrine Biosciences (NBIX) Head-To-Head Survey - June 29 at 2:38 PM logo Brokerages Expect Neurocrine Biosciences, Inc. (NBIX) Will Post Quarterly Sales of $7.06 Million - June 28 at 12:52 PM logoNeurocrine Biosciences, Inc. (NBIX) Receives Consensus Recommendation of "Buy" from Brokerages - June 27 at 9:26 AM logoZacks: Brokerages Anticipate Neurocrine Biosciences, Inc. (NBIX) to Announce -$0.64 Earnings Per Share - June 26 at 7:44 AM logoNeurocrine Biosciences, Inc. (NBIX) Upgraded to "Hold" at BidaskClub - June 21 at 5:34 PM logoFinancial Comparison: Juniper Pharmaceuticals (JNP) versus Neurocrine Biosciences (NBIX) - June 20 at 10:31 PM logoNeurocrine Biosciences Breaks Above 200-Day Moving Average - Bullish for NBIX - June 20 at 7:48 PM logoNeurocrine Biosciences (NBIX) Presents At Goldman Sachs 38th Annual Global Healthcare Conference - Slideshow - June 16 at 7:43 PM logoNeurocrine Biosciences (NBIX) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow - June 9 at 6:58 PM logoNeurocrine Biosciences to Present at the Goldman Sachs 38th Annual Global Healthcare Conference - June 9 at 6:58 PM logoValuEngine Upgrades Neurocrine Biosciences, Inc. (NBIX) to Sell - June 4 at 7:12 AM logoNeurocrine (NBIX) Reports Presentations on INGREZZA Capsules at Congress of Parkinson's Disease and Movement Disorders - June 2 at 8:08 PM logoNeurocrine Announces Presentations Related to INGREZZA® (valbenazine) Capsules at the 21st International Congress of Parkinson's Disease and Movement Disorders - June 2 at 8:08 PM logoNeurocrine Biosciences, Inc. (NBIX) Expected to Post Quarterly Sales of $7.06 Million - June 2 at 4:06 PM logoNeurocrine Biosciences to Present at the Jefferies 2017 Global Healthcare Conference - June 1 at 7:37 PM logoNeurocrine Biosciences, Inc. (NBIX) Given Average Rating of "Buy" by Brokerages - May 31 at 10:02 AM logoZacks: Analysts Expect Neurocrine Biosciences, Inc. (NBIX) Will Post Earnings of -$0.64 Per Share - May 31 at 10:02 AM logoNeurocrine Biosciences Becomes Oversold (NBIX) - May 30 at 6:27 PM logoNeurocrine Biosciences, Inc. (NBIX) Stock Rating Reaffirmed by Jefferies Group LLC - May 30 at 3:48 PM logoTechnical Reports on Generic Drugs Stocks -- Mylan, Allergan, Horizon Pharma ... - May 30 at 6:40 AM logoNeurocrine Biosciences, Inc. (NBIX) Given "Buy" Rating at Bank of America Corp - May 29 at 9:53 AM logoQ2 2017 EPS Estimates for Neurocrine Biosciences, Inc. Increased by Analyst (NBIX) - May 29 at 7:04 AM logoNeurocrine Biosciences, Inc. (NBIX) PT Lowered to $66.00 at Leerink Swann - May 27 at 6:22 PM logoNeurocrine Biosciences, Inc. (NBIX) Given Outperform Rating at BMO Capital Markets - May 27 at 4:32 PM logoShort Interest in Neurocrine Biosciences, Inc. (NBIX) Grows By 20.8% - May 26 at 9:24 PM logoJefferies Group Brokers Reduce Earnings Estimates for Neurocrine Biosciences, Inc. (NBIX) - May 26 at 2:00 PM logoNeurocrine Biosciences, Inc. (NBIX) Expected to Post Q3 2017 Earnings of ($0.37) Per Share - May 26 at 8:18 AM logoNBIX: P2 Study in Tourette’s Syndrome Does Not Meet Primary Endpoint; P2b Study to Start Before End of 2017 - May 26 at 4:40 AM logoNeurocrine Biosciences, Inc. (NBIX) PT Set at $57.00 by JPMorgan Chase & Co. - May 25 at 5:33 PM logoPiper Jaffray Companies Analysts Give Neurocrine Biosciences, Inc. (NBIX) a $68.00 Price Target - May 25 at 4:57 PM logoValuEngine Downgrades Neurocrine Biosciences, Inc. (NBIX) to Strong Sell - May 25 at 3:37 PM logoNeurocrine Biosciences, Inc. (NBIX) Given a $70.00 Price Target by Oppenheimer Holdings Inc. Analysts - May 25 at 3:02 PM logoNeurocrine Biosciences' (NBIX) "Buy" Rating Reaffirmed at Needham & Company LLC - May 24 at 11:26 PM logoNeurocrine Biosciences, Inc. (NBIX) Insider Dimitri E. Grigoriadis Sells 10,000 Shares - May 24 at 7:40 PM logoNeurocrine's Phase 2 Disappointment: Why The Company's Down, But Not Out - May 24 at 6:51 PM logoDid Neurocrine Just Leave The Door Open For Teva In Tourette's? - May 24 at 6:51 PM logoNuerocrine's Tourette's syndrome drug trial fails - May 24 at 10:30 AM logoBiotech Movers: Inovio, Neurocrine, Alnylam - May 24 at 10:30 AM logoInsider Selling: Neurocrine Biosciences, Inc. (NBIX) Insider Sells 9,960 Shares of Stock - May 23 at 7:46 PM logoNeurocrine Biosciences Inc. (NBIX) Is Falling After Phase 2 Study Fails - May 23 at 6:17 PM



Neurocrine Biosciences (NBIX) Chart for Wednesday, July, 26, 2017

This page was last updated on 7/26/2017 by Staff